-
公开(公告)号：US20130210082A1
公开(公告)日：2013-08-15
申请号：US13849420
申请日：2013-03-22
Applicant: Acorda Therapeutics, Inc.
Inventor： Anthony O. CAGGIANO , Andrea VECCHIONE , Jennifer IACI
IPC: C12N9/88
CPC classification number: A61K38/51 , A61K38/00 , C12N9/88 , C12Y402/0202 , C12Y402/02021
Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
-
2.发明申请COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS 有权组合物和使用CHONDROITINASE ABCI MUTANT的方法公开(公告)号：US20170028038A1
公开(公告)日：2017-02-02
申请号：US15230040
申请日：2016-08-05
Applicant: ACORDA THERAPEUTICS, INC.
Inventor： Anthony O. CAGGIANO , Andrea VECCHIONE , Jennifer IACI
IPC: A61K38/51
CPC classification number: A61K38/51 , A61K38/00 , C12N9/88 , C12Y402/0202 , C12Y402/02021
Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
Abstract translation: 本公开涉及软骨素酶ABCI的蛋白质和核酸突变体。 这种核酸突变体编码表现出改变的软骨素裂解酶活性的软骨素酶ABCI突变体酶或增强的抗应激物包括UV光或热的对灭活的抗性。 还提供了使用编码软骨素酶ABCI突变酶的核酸突变体的方法。
-
公开(公告)号：US20180073007A9
公开(公告)日：2018-03-15
申请号：US14535113
申请日：2014-11-06
Applicant: ACORDA THERAPEUTICS, INC.
Inventor： Elliott A. GRUSKIN , Anthony O. CAGGIANO , Gargi ROY , Jennifer IACI , Michael P. ZIMBER
CPC classification number: C12N9/88 , A61K35/30 , A61K38/00 , A61K38/51 , A61K45/06 , C07K14/005 , C07K19/00 , C07K2319/00 , C07K2319/03 , C07K2319/10 , C12N9/2408 , C12Y302/01035 , C12Y302/01036 , C12Y402/02001 , C12Y402/02004 , C12Y402/02005
Abstract: This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.
-
4.发明申请Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure 审中-公开神经调节蛋白或其片段的治疗剂量用于治疗或预防心力衰竭公开(公告)号：US20160129084A1
公开(公告)日：2016-05-12
申请号：US14772205
申请日：2014-03-06
Applicant: ACORDA THERAPEUTICS, INC.
Inventor： Anthony O. CAGGIANO , Anindita GANGULY , Jennifer IACI , Tom PARRY
IPC: A61K38/18 , A61K31/5513 , A61K9/00
CPC classification number: A61K38/1883 , A61K9/0019 , A61K31/5513 , A61K38/1808
Abstract: The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Abstract translation: 本发明涉及治疗和预防哺乳动物心力衰竭。 本发明提供了一种给药方案，其中通过施用包含表皮生长因子样结构域（例如神经胶质细胞生长因子2（GGF2）或其功能片段）的神经调节蛋白的肽所赋予的治疗益处被维持和/或增强， 同时最大限度地减少任何潜在的副作用。
-
Patent Agency Ranking
公开(公告)号：US20180066245A1
公开(公告)日：2018-03-08
申请号：US15789384
申请日：2017-10-20
Applicant: Acorda Therapeutics, Inc.
Inventor： Anthony O. CAGGIANO , Jennifer IACI , Andrea VECCHIONE , Elizabeth HUNTER
CPC classification number: C12N9/88 , A61K38/00 , A61K38/51 , C12Y402/02004
Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
-
6.发明申请COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS 有权组合物和使用CHONDROITINASE ABCI MUTANT的方法公开(公告)号：US20170009222A1
公开(公告)日：2017-01-12
申请号：US15216039
申请日：2016-07-21
Applicant: Acorda Therapeutics, Inc.
Inventor： Anthony O. CAGGIANO , Jennifer IACI , Andrea VECCHIONE , Elizabeth HUNTER
IPC: C12N9/88
CPC classification number: C12N9/88 , A61K38/00 , A61K38/51 , C12Y402/02004
Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
Abstract translation: 本发明的一个方面涉及软骨素酶ABCI的突变体。 这种软骨素酶ABCI突变体表现出改变的软骨素裂解酶活性或增加的抗应激因子灭活活性，包括暴露于紫外光或热。 还提供了使用软骨素酶ABCI突变酶的方法。
-
7.发明申请COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS 有权组合物和使用CHONDROITINASE ABCI MUTANT的方法公开(公告)号：US20150322422A1
公开(公告)日：2015-11-12
申请号：US14790075
申请日：2015-07-02
Applicant: ACORDA THERAPEUTICS, INC.
Inventor： Anthony O. CAGGIANO , Andrea VECCHIONE , Jennifer IACI
IPC: C12N9/88
CPC classification number: A61K38/51 , A61K38/00 , C12N9/88 , C12Y402/0202 , C12Y402/02021
Abstract: The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.
Abstract translation: 本公开涉及软骨素酶ABCI的蛋白质和核酸突变体。 这种核酸突变体编码表现出改变的软骨素裂解酶活性的软骨素酶ABCI突变体酶或增强的抗应激物包括UV光或热的对灭活的抗性。 还提供了使用编码软骨素酶ABCI突变酶的核酸突变体的方法。
-
公开(公告)号：US20150299687A1
公开(公告)日：2015-10-22
申请号：US14535113
申请日：2014-11-06
Applicant: ACORDA THERAPEUTICS, INC.
Inventor： Elliott A. GRUSKIN , Anthony O. CAGGIANO , Gargi ROY , Jennifer IACI , Michael P. ZIMBER
CPC classification number: C12N9/88 , A61K35/30 , A61K38/00 , A61K38/51 , A61K45/06 , C07K14/005 , C07K19/00 , C07K2319/00 , C07K2319/03 , C07K2319/10 , C12N9/2408 , C12Y302/01035 , C12Y302/01036 , C12Y402/02001 , C12Y402/02004 , C12Y402/02005
Abstract: This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.
Abstract translation: 本公开涉及能够用于治疗脊髓损伤和中枢神经系统（CNS）的相关病症的组合物，特别是包括蛋白多糖降解分子和能够阻断和/或超过神经元活性的组合物的组合物 生长抑制分子，以及融合蛋白，其包括蛋白聚糖降解结构域和能够阻断和或超过神经元生长抑制分子活性的结构域。
-
公开(公告)号：US20150190483A1
公开(公告)日：2015-07-09
申请号：US14480486
申请日：2014-09-08
Applicant: ACORDA THERAPEUTICS, INC.
Inventor： Anthony O. CAGGIANO , Jennifer IACI , Andrea VECCHIONE , Elizabeth MARKENSOHN
IPC: A61K38/51
CPC classification number: C12N9/88 , A61K38/00 , A61K38/51 , C12Y402/02004
Abstract: One aspect of the present invention relates to mutants of chondroitinase ABCI. Such chondroitinase ABCI mutants exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including exposure to UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.029 seconds)
